Recent research acquisitions have focused on describing the clinical spectrum associated with anti-MDA5 antibodies in Asian and non-Asian settings, in identifying predictors of RP-ILD and death, and on a deeper understanding of anti-MDA5 antibodies, whether as a directly pathogenic entity or as a marker of an underlying pathological process. Here, IFIH1 is linked to interstitial lung disease.